By acting on different CDK/cyclin complexes, CDC25 inhibitors would constitute interesting candidates to increase the therapeutic tools in the AML personalized treatment, and intense research is ongoing to give rise to new potent compounds [35, 36]. This evidence concerns the gene CDC25C and acute myeloid leukemia.